A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MedImmune
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2018 Status changed from active, no longer recruiting to completed.
- 04 Dec 2017 Planned End Date changed from 27 Feb 2018 to 22 Jan 2018.